The use of intensity-modulated radiation therapy compared with conformal radiation and proton therapy was associated with less gastrointestinal morbidity in patients with non-metastatic prostate cancer, according to a study published April 18 in the Journal of the American Medical Association.
The study also found that patients treated with IMRT were less likely to receive additional cancer therapy compared with those treated with the older conformal radiation therapy
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?